BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1778178)

  • 1. Insulin as an effector of human ovarian and adrenal steroid metabolism.
    Nestler JE; Strauss JF
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):807-23. PubMed ID: 1778178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgens in polycystic ovary syndrome: the role of exercise and diet.
    Giallauria F; Palomba S; Vigorito C; Tafuri MG; Colao A; Lombardi G; Orio F
    Semin Reprod Med; 2009 Jul; 27(4):306-15. PubMed ID: 19530064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effects of hyperinsulinmia and insulin-like growth factor-1 on hyperandrogenism in polycystic ovarian syndrome].
    Liang X; Zhuang G; Fan Q
    Zhonghua Yi Xue Za Zhi; 1997 Apr; 77(4):266-9. PubMed ID: 9596926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic ovary syndrome in obese adolescents.
    Stanley T; Misra M
    Curr Opin Endocrinol Diabetes Obes; 2008 Feb; 15(1):30-6. PubMed ID: 18185060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
    Loverro G; Lorusso F; De Pergola G; Nicolardi V; Mei L; Selvaggi L
    Gynecol Endocrinol; 2002 Jun; 16(3):217-24. PubMed ID: 12192894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disturbances of androgen secretion and metabolism in polycystic ovary syndrome.
    Lobo RA
    Clin Obstet Gynaecol; 1985 Sep; 12(3):633-47. PubMed ID: 2933204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome.
    Panidis D; Rousso D; Koliakos G; Kourtis A; Katsikis I; Farmakiotis D; Votsi E; Diamanti-Kandarakis E
    Fertil Steril; 2006 Jun; 85(6):1778-83. PubMed ID: 16650418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperinsulinemia and ovarian hyperandrogenism. Cause and effect.
    Barbieri RL; Hornstein MD
    Endocrinol Metab Clin North Am; 1988 Dec; 17(4):685-703. PubMed ID: 3058472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic ovary syndrome: obesity, insulin resistance, hyperandrogenism.
    Lo Dico G; Alongi G; Savatteri L; Rini GB; Mascellino MR; Di Fede G; Rizzo G
    Acta Eur Fertil; 1989; 20(5):309-13. PubMed ID: 2700062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hirsutism and virilism in women.
    Kirschner MA
    Spec Top Endocrinol Metab; 1984; 6():55-93. PubMed ID: 6084314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome].
    Vrbíková J; Hill M; Stárka L; Cibula D; Snajderová M; Sulcová J; Vondra K; Bendlová B
    Cas Lek Cesk; 2001 Nov; 140(22):688-94. PubMed ID: 11789058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroidogenesis in human polycystic ovary.
    Mahajan DK
    Endocrinol Metab Clin North Am; 1988 Dec; 17(4):751-69. PubMed ID: 3143567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroidogenic alterations and adrenal androgen excess in PCOS.
    Doi SA; Al-Zaid M; Towers PA; Scott CJ; Al-Shoumer KA
    Steroids; 2006 Sep; 71(9):751-9. PubMed ID: 16781743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of chronic hyperandrogenism and/or administered central nervous system insulin on ovarian manifestation and gonadotropin and steroid secretion.
    Allon MA; Leach RE; Dunbar J; Diamond MP
    Fertil Steril; 2005 Apr; 83 Suppl 1():1319-26. PubMed ID: 15831308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Premature androgenic alopecia and insulin resistance. Male equivalent of polycystic ovary syndrome?
    Starka L; Duskova M; Cermakova I; Vrbiková J; Hill M
    Endocr Regul; 2005 Dec; 39(4):127-31. PubMed ID: 16552990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome.
    Nestler JE; Jakubowicz DJ; Iuorno MJ
    J Pediatr Endocrinol Metab; 2000; 13 Suppl 5():1295-8. PubMed ID: 11117673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients.
    Musso C; Cochran E; Javor E; Young J; Depaoli AM; Gorden P
    Metabolism; 2005 Feb; 54(2):255-63. PubMed ID: 15690321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters.
    Carmina E; Orio F; Palomba S; Longo RA; Lombardi G; Lobo RA
    Fertil Steril; 2005 Aug; 84(2):413-9. PubMed ID: 16084883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.